This technology identifies epidermal growth factor receptor (EGFR) gene fusion events that are associated with various cancers, enabling diagnosis and targeted treatment.
Current cancer treatments typically involve combinations of chemotherapy, surgery, and radiation. However, these therapies can have many side effects and are difficult to implement with aggressive cancers. Targeted drug therapies present a favorable alternative, since they are tailored to a specific form of cancer, increasing the likelihood for positive outcomes and reduced treatment associated side effects. While various oncogenes for targeted approaches have been discovered, there remains a need to understand downstream signaling targets and identify commonalities among diverse cancers, in order to facilitate personalized oncotherapy for all cancer patients.
This technology identifies specific EGFR fusion events and related downstream signaling targets associated with roughly 3-8% of cases across various cancers, including aggressive cancers with low survival rates. The technology implicates specific fusion events as integral to oncogenesis, and provides methods for decreasing expression of EGFR fusion proteins and administering targeted drug treatments. Additionally, this technology provides an innovative treatment strategy for aggressive cancers such as glioblastoma, which has a median survival rate of 12-15 months and few current treatment options. This technology has wide applicability for diagnosis and targeted treatment of diverse cancers, and may facilitate the development of more selective inhibitors against gene fusion associated cancers.
The causative effect of EGFR fusion events, as well as the therapeutic benefit of EGFR inhibitors, has been demonstrated in humanized mouse models of cancer.
IR CU13242
Licensing Contact: Ron Katz